2016: The alliance pairs preclinical and clinical teams from the MD Anderson with Adaptimmune Therapeutics’ Specific Peptide Enhanced Affinity Receptor (SPEAR®) T-cell technology platform that enables the identification of targets (e.g., MAGE-A10 and MAGE-A4) expressed on solid and hematological cancers and to develop affinity-enhanced TCRs with optimal potency and specificity against them. The gene discussed is MAGEA4; the disease is hematopoietic and lymphoid cell neoplasm.